Deals Report: Bispecific space continues to foster partnerships

The latest biopharma partnerships include at least three licensing deals in the hot bispecific space in the past week, even as a collaboration between BioNTech and Genmab for one such late-stage asset fizzled.

Last week saw one notable M&A announcement — Otsuka Holdings Co. Ltd. (Tokyo:4578) acquired  Jnana Therapeutics Inc. for $800 million. The takeout, which includes $325 million in potential development and regulatory milestones, gives Otsuka a small molecule SLC6A19 inhibitor to treat phenylketonuria. ...